Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Status:
Completed
Trial end date:
2017-05-11
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the antiviral efficacy of therapy with
ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and to evaluate the safety and
tolerability of LDV/SOF FDC and sofosbuvir (SOF) + ribavirin (RBV) in participants with
chronic genotype 2 hepatitis C virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir